scholarly journals Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

2019 ◽  
Vol 26 (5) ◽  
pp. 1045-1053 ◽  
Author(s):  
Keith L. Knutson ◽  
Matthew S. Block ◽  
Nadine Norton ◽  
Courtney L. Erskine ◽  
Timothy J. Hobday ◽  
...  
2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3059-3059
Author(s):  
D. Wallace ◽  
M. Disis ◽  
A. Coveler ◽  
D. Higgins ◽  
J. Childs ◽  
...  

3059 Background: Studies have demonstrated that the level of HER2 gene amplification in breast cancer, assessed by fluorescence in situ hybridization (FISH), correlates with favorable clinical response after treatment with trastuzumab. We questioned whether HER2 gene amplification impacted the development of HER2-specific T-cell immunity following immunization with a HER2 vaccine. Methods: Patients with HER2+ stage III or IV breast cancer, treated to complete remission or stable bone only disease, were enrolled in one of two concurrent clinical trials of HER2-specific vaccines. Eligibility criteria between the two studies were similar. Patients received either a plasmid DNA-based vaccine encoding the HER2 intracellular domain or a peptide-based vaccine composed of 3 HER2 class II epitopes. Peripheral blood was assessed for HER2-specific T-cell responses by interferon gamma (IFN-g) ELISPOT prior to, immediately after, and 6 months to 1 year after the end of vaccinations. Both immune response and FISH data were available on 31 patients. Results: Correlation of FISH levels to IFN-g spots/well in evaluable patients revealed the level of HER2 gene amplification was not related to the presence of pre-existent HER2-specific T-cell immunity prior to vaccination (p=0.43), the generation of a HER2-specific immune response after vaccination (p=0.35), or the persistence of the HER2-specific T-cell response (p=0.33). However, the magnitude of the T-cell response achieved was less as HER2 gene amplification increased (p=0.05). Conclusions: The level of HER2 gene amplification in the primary tumor can adversely impact the magnitude of HER2-specific T-cell immunity achieved after vaccination. No significant financial relationships to disclose.


2003 ◽  
Vol 105 (2) ◽  
pp. 221-225 ◽  
Author(s):  
Dirk Nagorsen ◽  
Carmen Scheibenbogen ◽  
Gerhard Schaller ◽  
Binta Leigh ◽  
Alexander Schmittel ◽  
...  

2005 ◽  
Vol 132 (4) ◽  
pp. 265-274 ◽  
Author(s):  
Brigitte Gückel ◽  
Christine Rentzsch ◽  
Maria-Dorothea Nastke ◽  
Alexander Marmé ◽  
Ines Gruber ◽  
...  

2021 ◽  
Author(s):  
Franz Josef Obermair ◽  
Florian Renoux ◽  
Sebastian Heer ◽  
Chloe Lee ◽  
Nastassja Cereghetti ◽  
...  

Understanding the mechanisms of immune evasion is critical for formulating an effective response to global threats like SARS-CoV2. We have fully decoded the immune synapses for multiple TCRs from acute patients, including cognate peptides and the presenting HLA alleles. Furthermore, using a newly developed mammalian epitope display platform (MEDi), we determined that several mutations present in viral isolates currently expanding across the globe, resulted in reduced presentation by multiple HLA class II alleles, while some increased presentation, suggesting immune evasion based on shifting MHC-II peptide presentation landscapes. In support, we found that one of the mutations present in B1.1.7 viral strain could cause escape from CD4 T cell recognition in this way. Given the importance of understanding such mechanisms more broadly, we used MEDi to generate a comprehensive analysis of the presentability of all SARS-CoV-2 peptides in the context of multiple common HLA class II molecules. Unlike other strategies, our approach is sensitive and scalable, providing an unbiased and affordable high-resolution map of peptide presentation capacity for any MHC-II allele. Such information is essential to provide insight into T cell immunity across distinct HLA haplotypes across geographic and ethnic populations. This knowledge is critical for the development of effective T cell therapeutics not just against COVID-19, but any disease.


2000 ◽  
Vol 165 (1) ◽  
pp. 528-532 ◽  
Author(s):  
Keishi Fujio ◽  
Yoshikata Misaki ◽  
Keigo Setoguchi ◽  
Sumiyo Morita ◽  
Kimito Kawahata ◽  
...  

2007 ◽  
Vol 67 (21) ◽  
pp. 10546-10555 ◽  
Author(s):  
Susan M. Domchek ◽  
Adri Recio ◽  
Rosemarie Mick ◽  
Carolyn E. Clark ◽  
Erica L. Carpenter ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3010-3010 ◽  
Author(s):  
L. G. Salazar ◽  
V. Goodell ◽  
M. O'Meara ◽  
K. Knutson ◽  
Y. Dang ◽  
...  

3010 Background: Our initial vaccine studies showed that optimally treated breast cancer patients can be immunized against HER2 during active immunization. The majority of patients developed T-cell immunity to HER2 peptides and protein and also epitope spreading (ES). The goal of this study was to determine if patients previously immunized with a HER2 vaccine had persistent immunity years after active immunization and to assess their clinical outcome in terms of overall survival (OS). Methods: Subjects eligible for this IRB-approved long term follow-up (LTFU) study: (1) had HER2+ breast cancer and were immunized between 1996–1999 in a phase I HER2 peptide vaccine trial, (2) were at least 1 year out from their last vaccine, and (3) if donating blood samples could not be receiving chemotherapy. 52 patients (37 stage IV, 15 stage III) were identified and 21/52 patients (12 stage IV, 9 stage III) were determined to be living. All 21 subjects were contacted by letter and sent a LTFU Questionnaire. OS was defined as the time between date of vaccine study entry and death or last follow-up and was estimated using the Kaplan-Meier method. Cox proportional hazards were used to determine associations between OS and known clinical and vaccine-related immunologic factors; analyses included all 52 subjects. Long-term T-cell immunity was evaluated using IFN-γ ELISPOT assay. Results: Median follow-up time for the 21 patients still alive was 112 months (range, 104–126 months). Blood samples were collected in 10/21 subjects and 6/8 (75%) evaluble patients had persistent T-cell immunity to immunizing HER2 peptides; and 7/8 patients (88%) had T-cell immunity specific for HER2 protein and peptides not contained in their immunizing mix (defined as ES). In multivariate analysis, number of chemotherapy regimens prior to vaccination (HR=5.7 (CI 95%, 1.5–23; p=<0.001)), and development of ES after HER2 vaccination (HR=0.34 (CI 95%, 0.12–1.0; p=0.05)) were independent predictors of OS. Median OS for 33 subjects who developed ES was 84 months vs 25 months for 16 subjects who did not develop ES. Conclusions: HER2-specific T-cell immunity elicited with active immunization is durable years after vaccination has ended and the generation of ES is an independent predictor of OS. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document